Abstract: Provided is a composition for the treatment of osteoarthritis using iPSC-derived mitochondria. Therefore, it was confirmed that the iPSC-derived mitochondria of the present disclosure increased the transplant ability into chondrocytes, suppressed the expression of the MMP series, which were cartilage metabolic factors, and suppressed the death of chondrocytes. In addition, it was confirmed that the iPSC-derived mitochondria suppressed damage to joint tissue in an osteoarthritis animal model, reduced immune cells, and increased immune osteoarthritis-causing regulatory cells. In addition, it was confirmed that the expression of UCP2 in iPSC-derived mitochondria was significantly increased compared to mitochondria isolated from other origin cells, and that UCP2 was closely related to the treatment effect of osteoarthritis caused by mitochondrial transplantation. In addition, it was confirmed that iPSC-derived mitochondria overexpressing UCP2 improves osteoarthritis as a cartilage regeneration effect.

Abstract: The present invention relates to a pharmaceutical composition comprising a novel compound as an active ingredient for prevention or treatment of transplant rejection. The novel compound SD911 of the present invention was identified to repress the migration of immune cells, increase the engraftment and viability of a grafted tissue, and regulate immune cells. In addition, it was found in a kidney transplantation model that the compound restrained human PBMC from suppressing the engraftment and damaging renal tissues and downregulated the expression of the inflammatory cytokine IL-17, with the consequent effective prevention and treatment of transplant rejection.

Abstract: The present invention relates to a composition for preventing or treating mitochondrial diseases caused by immunosuppressants, and immune diseases, containing metformin and, more specifically, to a composition for treating mitochondrial diseases caused by immunosuppressants, containing metformin; a pharmaceutical composition for preventing or treating immune diseases, containing, as active ingredients, metformin and an immunosuppressant, which is a target of rapamycin inhibitor (mTOR inhibitor); and a pharmaceutical composite formulation for preventing or treating immune diseases, containing, as ingredients, metformin and a mammalian target of rapamycin inhibitor, wherein the metformin and mammalian target of rapamycin inhibitor are administered simultaneously or separately, or administered in a predetermined sequence.

Abstract: Provided is a composition for alleviating nephrotoxicity caused by an immunosuppressive drug, including metformin, and a composition for preventing or treating an immune disease, including the same. Further, the composition provided can be useful in improving a treatment effect on diseases requiring immunosuppression by effectively alleviating a decline in renal function caused due to side effects of conventional immunosuppressive drugs, and can also be useful in preventing or treating organ transplant rejection, autoimmune diseases, inflammatory diseases and the like since various methods of co-administering a conventional immunosuppressive drug and metformin are suggested to reduce nephrotoxic side effects of conventional immunosuppressive drugs and maximize immunosuppressive or immunomodulatory effects.

Abstract: Provided is a composition for alleviating nephrotoxicity caused by an immunosuppressive drug, including metformin, and a composition for preventing or treating an immune disease, including the same. Further, the composition provided can be useful in improving a treatment effect on diseases requiring immunosuppression by effectively alleviating a decline in renal function caused due to side effects of conventional immunosuppressive drugs, and can also be useful in preventing or treating organ transplant rejection, autoimmune diseases, inflammatory diseases and the like since various methods of co-administering a conventional immunosuppressive drug and metformin are suggested to reduce nephrotoxic side effects of conventional immunosuppressive drugs and maximize immunosuppressive or immunomodulatory effects.

Abstract: The present invention relates to a road restoration block for covering eliminated pavements during various road constructions conducted by eliminating some of or the entire existing road pavements, and more specifically, to a road restoration block, which can quickly and safely cover the eliminated pavements by providing blocks that are simply carried, disposed, and disassembled with strong coupling power to the upper part of the eliminated pavements so that people and cars may pass even when the constructions are in progress, thereby providing a safe and pleasant construction environment by preventing the traffic congestion caused by the constructions.

Abstract: The present invention relates to a road restoration block for covering eliminated pavements during various road constructions conducted by eliminating some of or the entire existing road pavements, and more specifically, to a road restoration block, which can quickly and safely cover the eliminated pavements by providing blocks that are simply carried, disposed, and disassembled with strong coupling power to the upper part of the eliminated pavements so that people and cars may pass even when the constructions are in progress, thereby providing a safe and pleasant construction environment by preventing the traffic congestion caused by the constructions.